Investor Relations

EKR is a privately held company with investment support from leading healthcare venture capital and private equity firms. EKR’s most recent financing was completed in March 2008. At that time, EKR successfully raised over $145 million in combined debt and equity financing.

The equity funding round, amounting to $50 million, was led by then new investors MPM Capital and LLR Partners. Also participating were prior investors Quaker BioVentures and the Garden State Life Sciences Venture Fund managed by Quaker. Original institutional investors NewSpring Capital and ESP Equity Partners also participated. The debt financing was provided by GE Healthcare Financial Services.

Since EKR’s inception in November 2005 through the financing round completed in March 2008, EKR raised approximately $180 million of which a portion was used to fund the acquisition of the company’s first four commercial products: Gelclair®, DepoDur®, Cardene® IV, and Retavase®.

Correspondingly, in this comparatively brief period of less than two-and-a-half years, EKR advanced from a start-up situation to a profitable, cash-flow positive commercial enterprise.

For additional information contact

Darren Pincus
Sr. Director, Corporate Development
1545 Route 206 South, 3rd Floor
Bedminster, NJ 07921
Tel: 908.997.0709
Fax: 908.997.0787
d.pincus@ekrtx.com